Table 1 Population characteristics
From: Routine screening for psychosocial distress following hematopoietic stem cell transplantation
Variables | Signed consent and participated | Signed consent, did not participate | Never signed consent | P-value |
|---|---|---|---|---|
N | 61 | 19 | 55 | Â |
Median age in years (range) | 49 (20–72) | 49 (26–69) | 47 (20–70) | NS |
Male sex (%) | 31 (51%) | 10 (53%) | 35 (64%) | NS |
White race (%) | 60 (98%) | 18 (95%) | 48 (87%) | P1=0.02 |
Disease stage at transplant (%) | Â | Â | Â | NS |
 Good | 6 (10%) | 2 (11%) | 5 (9%) |  |
 Intermediate | 44 (72%) | 13 (68%) | 35 (64%) |  |
 Poor | 11 (18%) | 4 (21%) | 15 (27%) |  |
Type of transplant (%) | Â | Â | Â | NS |
 Autologous | 27 (44%) | 10 (53%) | 16 (29%) |  |
 Allogeneic, nonmyeloablative | 17 (28%) | 2 (11%) | 18 (33%) |  |
 Allogeneic, myeloablative | 17 (28%) | 7 (37%) | 21 (38%) |  |
Stem cell source | Â | Â | Â | NS |
 Bone marrow | 6 (10%) | 2 (11%) | 4 (7%) |  |
 Peripheral blood | 54 (88%) | 17 (89%) | 51 (93%) |  |
 Bone marrow and peripheral blood | 1 (2%) | 0 (0%) | 0 (0%) |  |
T-cell depletion (%) | 2 (3%) | 2 (11%) | 3 (5%) | NS |
Deaths within first 100 days | 3 (5%) | 5 (26%) | 9 (16%) | P2=0.02 |
Median follow-up of survivors, months (range) | 6 (3–12) | NA | NA |  |
